2017-06-08 18:47:44 UTC

Advent of Biosimilar Products in US GI Practice


1.5 hours


Learn about how biosimilars are used in the practice of gastroenterology in the US from this recording of the live session held during DDW 2017 in Chicago (recorded May 9, 2017). Panelists and presentations include:

  • Introduction to Biosimilars (15 minutes)
    Gary R. Lichtenstein, MD, AGAF
  • The US Biosimilars Regulatory Pathway (20 minutes)
    M. Stacey Ricci, M.Eng., Sc.D.
  • Clinical Considerations In Use Of Biosimilars For Gastrointestinal Disorders (20 minutes)
    Brian G. Feagan, MD
  • Why Patients Should Know About Biosimilars (20 minutes)
    David T. Rubin, MD, AGAF
  • Panel Discussion (15 minutes)

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

This session is sponsored by the AGA Biosimilars Advisory Panel, Clinical Practice, Immunology, Microbiology & Inflammatory Bowel Diseases, and is a collaboration of the AGA Institute and the Crohn’s and Colitis Foundation.


Claim CME

CME Information

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

CME expiration date: July 19, 2019

Faculty Relationship and Financial Disclosures

Click here to view financial disclosures for presenters

Planning Committee

Gary R. Lichtenstein, MD, AGAF

  • Consultant: Abbvie, Alaven, Celgene/Santarus/Receptos, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Reagent, Pfizer, Prometheus, Salix Pharmaceuticals,
  • Shire, Takeda, UCB
  • Grant/Research Support: Celgene/Santarus/Receptos, Takeda
  • Honoraria: Clinical Advances in Gastroenterology, Ironwood, McMahon Publishing,
  • Merck, Romarck, Springer
  • Royalty: SLACK, Inc.

AGA Staff

Maura H. Davis
Disclosed no relevant financial relationships.

Monique S. Dyson, MS, CHES
Disclosed no relevant financial relationships.

Alison Kim, PhD
Disclosed no relevant financial relationships.

Crohn’s & Colitis Foundation Staff

Orna Ehrlich
Disclosed no relevant financial relationships.

Laura Wingate
Disclosed no relevant financial relationships.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health-care professionals who treat GI disorders.

More on Biosimilars

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.

Get Your Questions Answered on Biosimilar Therapies

Dec. 7, 2017

Join inflammatory bowel disease (IBD) experts on Dec. 11, 2017, 8-8:45 p.m. ET, for a free webinar on biosimilar therapies.

Can You Explain Biosimilars to Patients?

Oct. 25, 2017

AGA is taking the lead in educating health care professionals and their patients about biosimilars and how they can play a role in IBD patient care.